Skip to NavigationSkip to content

Top Ten most popular articles on Pharmafile.com this week

Published on 09/10/20 at 11:30am

The top ten news stories this week focus on clinical trial data, as Amgen and Novartis have revealed new five-year Phase 2 data during the Migraine Trust Virtual Symposium for their calcitonin gene-related peptide (CGRP) antagonist Aimovig (erenumab-aooe) in the treatment of patients with episodic migraine (EM), while Remdesivir has a "favourable" benefit/risk profile in COVID-19 but more data needed, the DSRU review argues.

In other news, Johnson & Johnson have agreed to pay over $100 million to settle more than 1,000 lawsuits that blame the company’s talc baby powder for causing cancer, GlaxoSmithKline has told its employees to turn off the new NHS coronavirus tracking app at work as it could be disruptive to its business.

1. Enlivex's Allocetra improves COVID-19 recovery times, early data show

Israeli immunotherapy firm Enlivex Therapeutics has released tentatively positive data for its therapy Allocetra as a treatment for patients with severe and critical forms of COVID-19.

2. GSK tells UK staff to turn off NHS COVID-19 tracking app while at work

GlaxoSmithKline has told its employees to turn off the new NHS coronavirus tracking app at work as it could be disruptive to its business, according to The Guardian.

3. FDA defies advisory panel recommendation, rejecting Mesoblast's Ryoncil in paediatric steroid-refractory acute graft versus host disease

The FDA has issued a surprising rejection of Mesoblast’s Ryoncil (remestemcel-L) as a treatment for paediatric steroid-refractory acute graft versus host disease (SR-aGVHD), it has been reported.

4. Eli Lilly’s antibody COVID-19 therapy reduces virus levels and hospitalisations

Eli Lilly is seeking Emergency Use Authorization from the FDA after releasing interim data based on early trial results.

5. Remdesivir has a "favourable" benefit/risk profile in COVID-19 but more data needed, DSRU review argues

Southampton’s Drug Safety Research Unit (DSRU) has released a systematic benefit/risk analysis of Gilead’s antiviral drug remdesivir in the treatment of COVID-19, published in Drug Safety.

6. ViiV's two-drug regimen proves non-inferior in treatment-naive HIV-1

ViiV Healthcare has taken the opportunity at the HIV Glasgow 2020 Virtual Congress to unveil three-year Phase 3 data from two studies examining the efficacy of dolutegravir in combination with lamivudine for the treatment of HIV-1 in adult patients who have not received prior therapy.

7. Aimovig reduces frequency of episodic migraines, five-year data reveals

Amgen and Novartis have revealed new five-year Phase 2 data during the Migraine Trust Virtual Symposium for their calcitonin gene-related peptide (CGRP) antagonist Aimovig (erenumab-aooe) in the treatment of patients with episodic migraine (EM).

8. Johnson & Johnson to spend over $100m to settle 1,000 talc powder lawsuits

Johnson & Johnson have agreed to pay over $100 million to settle more than 1,000 lawsuits that blame the company’s talc baby powder for causing cancer.

9. Covis Group to acquire AMAG Pharmaceuticals in $647m deal

Luxembourg-based Covis Group is set to acquire Massachusetts-based AMAG Pharmaceuticals in a new deal worth approximately $647 million on an enterprise basis, including debt, it has emerged.

10. EMA launches rolling regulatory review of Pfizer and BioNTech's COVID-19 vaccine

European Medicines Agency has launched a “rolling review” of the promising COVID-19 vaccine candidate BNT162b2 currently in development from BioNTech and Pfizer, following a similar protocol to the one it has adopted to evaluate a rival vaccine from AstraZeneca and the University of Oxford.

Conor Kavanagh

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches